바로가기메뉴

본문 바로가기 주메뉴 바로가기
 
 

logo

  • ENGLISH
  • P-ISSN3022-6805
  • E-ISSN3022-6791
  • KCI

ISSN : 3022-6805

논문 상세

이전 다음
논문 투고

Vol.9 No.4

PDF Citation Share

Therapeutic Effect of Majoon Mundi and Qairooti Karnab in Dā al-Ṣadaf (Psoriasis): A Case Series

셀메드 / CELLMED, (P)3022-6805; (E)3022-6791
2019, v.9 no.4, pp.8-8
Gulnaz Fatima Siddiqui (Central Research Institute of Unani Medicine)
Shahid Akhtar Siddiqui (MLN Medical College)
Arzeena Jabeen (Central Research Institute of Unani Medicine)
Qamaruddin (Central Research Institute of Unani Medicine)
Munawwar Husain Kazmi (Central Research Institute of Unani Medicine)
Gulnaz, F. S. , Shahid, A. S. , Arzeena, J. , Qamaruddin, , & Munawwar, H. K. (2019). . , 9(4), 8-8.

Abstract

A cuttlefish bone is not a bone, but the internal shell of the Cuttlefish/ sepia officinalis, a small, squid-like cephalopod of phylum molusca, an animals of the order Sepiida. Cuttlefish bone comprises up to 90 percent of its content of calcium carbonate with the abundance of different bioinorganic elements such as magnesium, strontium, iron, even trace amounts of copper, zinc, aragonite and β-chitin which makes it extremely valuable and worthwhile to be used for biomedical research. Unani system of medicine has been using cuttlefish bone under the name of ‘kafe dariya’ for the treatment various disorders and ailments since centuries. Unani scholars were well aware of the valuable medical and cosmetologically aspect of cuttlefish bone. However, the drug has been forgotten for its beneficial effect and went deep away from the scientific researches. The purpose of the present review is to highlight and revive the data on cuttlefish and cuttlefish bone for its morphology, composition, types, pharmacological actions, temperament, therapeutic dosage, contraindications, correctives, alternatives and therapeutic uses with special reference of Unani medicine to attain its the beneficial features in biomedical sciences.

keywords
Sepia, cuttlefish bone, kafe dariya, Unani medicine, sepia officinalis

참고문헌

1.

Al, Tūr S.H. et al. “Kāmil Al-Tashkhīs.”(Lahore, India: Bu’ IdāraTarjama al-Ṭibb).

2.

Aleem HMA, Khan N. Sharah-e-Rubaiyat: Tibb-e-Yousufi. (Lucknow, India: Munshī Naval Kishore).

3.

Alī., Syed Saiʻfuddīn. Unani Adwiya Mufradā. (New Delhi, India: Taraqqī Urdu Beurea), 1984.

4.

Alīm, Tabībā Shagufta. Amrāḍ-i-Jild. (Aligarh, India: Sabā), 2002.

5.

Anonymous. Qarabadin-i Majidi. (New Delhi, India: All India Tibbi Unani Congress.), 1951.

6.

Ansari S, Zeenat F, Ahmad W, Ahmad I. Therapeutics and Pharmacology of Gul-e-Surkh (Rosa Damascena Mill): An Important Unani Drug. International Journal of Advances in Pharmacy Medicine and Bioallied Sciences. 2017;5(3):195-205

7.

Behl PN. Practice of Dermatology. 9th ed. (New Delhi, India: CBS Publishers and Distributor), 2000.

8.

Bolognia JL, Jorizzo JL, Rapini RP. Dermatology. 2nd ed. (London, UK: MOSBY Elsevier). 2008.

9.

Bonifati C, Ameglio F. Cytokines in Psoriasis. International Journal of Dermatology. 1999;38(4): 241-51.

10.

British Association of Dermatologists. Psoriasis area and severity index (pasi) worksheet. Available at: http://www.bad.org.uk/shared/get-file.ashx?id=1654&itemtype=document. (Accessed on October 21, 2019).

11.

Danielsen K, Olsen AO, Wilsgaard T, Furberg AS. Is the Prevalence of Psoriasis Increasing? A 30-Year Follow-up of a Population-Based Cohort. The British journal of dermatology. 2013;168(6): 1303-10.

12.

Fredriksson T, Pettersson U. Severe Psoriasis — Oral Therapy with a New Retinoid. Dermatology.1978;157(4): 238-44.

13.

Ghanī. Khazā’ in Al-Adwiya. (New Delhi, India: Iādra Kitāb al-Shifā), 2011.

14.

Habashy J, Robles DT, James WD, Meffert J. Psoriasis. Available at: https://emedicine.medscape.com/article/1943419-overview (Accessed on October 21, 2019).

15.

Haslett C, Davidson S. Davidsons Principles and Practice of Medicine. (London, UK: Churchill Livingstone), 2002.

16.

Ibn Rushd, Abul Walid Mohammad. Kitāb Al-Kulliyyāt, Urdū Tarjamah. 2nd ed. (New Delhi, India: CCRUM Ministry of Kabeeruddin HM. Al Qarabadeen. (New Delhi, India: CCRUM.), 2006.

17.

Khan HA. Majma Al-Bahrain. (Lucknow, India: Matba Munshi Naval Kishore)

18.

Khan HMA. Akseer-e-Azam. Vol 4. (Kanpur, India: MatbaNizam).

19.

Law RM, Kwa PG. Dermatologic Disorders. In Pharmacotherapy: A Pathophysiological Approach, (New York, USA: McGraw-Hill Medical Publishing Division), 2011, 1693-1706.

20.

Lone AH, Ahmad T, Naiyar AH. Clinical Evaluation of Efficacy of Majoon Ushba and Roghane Hindi in the Management of Psoriasis: A Randomized Single-Blind, Placebo-Controlled Study. Journal of Ayurveda and Integrative Medicine. 2011;2(1): 26-31.

21.

Majūsī. Kāmil Al-Ṣāna. (Urdu Translation by Kantūri GH).Vol 1,2. (New Delhi, India: Idārā Kitbāb al- Shifā), 2010.

22.

Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361(5):496-509.

23.

Papadakis MA, McPhee ST, Rabow MW. Current Medical Diagnosis & Treatment, (NY, USA: McGraw-hill Education) 2017.

24.

Peternel S, Prpić-Massari L, Guina T, Novak S, Brajac I, Kastelan M. Treatment of Severe Psoriasis with Infliximab: Report of Two Cases. Acta Dermatovenerol Croat. 2009;17(3):204-6.

25.

Rafiquddin M. Kanaz Al-Adwiya Mufrada. (Aligarh, India: Muslim University Press), 1985.

26.

Rahman, Mahfoozur et al. 12 Endocrine, Metabolic & Immune Disorders-Drug Targets Classical to Current Approach for Treatment of Psoriasis: A Review, 2012.

27.

Sainani GS. A.P.I. TextBook of Medicine, 6th Ed. (Mumbai, India: Association of Physicians of India), 1999.

28.

Sarac, G, Koca TT, Baglan T. A Brief Summary of Clinical Types of Psoriasis. North Clin Istanb. 2016;3(1): 79-82.

29.

Schön MP1, Boehncke WH. Psoriasis. The New England journal of medicine. 2005;352(18): 1899-1912.

셀메드

논문 투고 OA 정책